Get started
Work

Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Year: 2013
Type: article
Abstract: Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 According to data from the Massachusetts Male Aging Study, up to 52% of men between the ages of 40 and 70 are affected by ED.2 Based on findings from the 2001–2002 National Health and Nutrition Examination Survey (NHANES), it is estimated that 18.4% of men in the U.S. who are 20 years of age and older have ED. Although ED is not an inevitable consequence of aging, there is a positive correlation with age. The prevalence of 5.1% in 20- to 39-year-old men increases to 70.2% in men 70 years of age and older. Because the etiology of ED often involves a combination of vascular, neurological, endocrinological, and psychological factors, the condition is not limited to elderly men. Other risk factors such as cardiovascular disease, hypertension, diabetes, hypercholesterolemia, and smoking have been strongly associated with an increased prevalence of ED.3 Historically, a limited understanding of the physiological mechanism of erections restricted the treatment of ED to vacuum-constriction devices, prosthetic implants, intracavernosal injections, and intraurethral suppositories.4 Since its advent, the class of agents known as type-5 phosphodiesterase (PDE5) inhibitors has revolutionized the management of ED. PDE5 inhibitors have become the first-line therapy for ED, as recommended by the American Urological Association (AUA) and the European Association of Urology (EAU).4,5 The four oral PDE5 inhibitors commercially available in the U.S. are sildenafil (Viagra, Pfizer), vardenafil (Levitra and Staxyn, Bayer/GlaxoSmithKline), tadalafil (Cialis, Eli Lilly), and a more recently approved drug, avanafil (Stendra, Vivus). The expansion of this class has allowed for greater flexibility in prescribing based on individual response.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W1831214161
FWCI: 1.631
Cites: 16
Cited by: 153
Related to: 10